Get Your Cash Out of U.S. Banks Immediately
Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.
Click here to learn more.

CU6 Insider Trading

Insider Ownership Percentage: 60.48%
Insider Buying (Last 12 Months): A$63,185.76
Insider Selling (Last 12 Months): A$0.00

Clarity Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Clarity Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Clarity Pharmaceuticals Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 06/27/2022 12:08 PM ET

This chart shows the closing price history over time for CU6 up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Seven millionaires secretly enable market shock?
A fraud expert to the FBI just shared a surprising new prediction. Own stocks? Watch it now.
Watch it now.

Clarity Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2023Colin BigginInsiderBuy287,208A$0.22A$63,185.76
12/8/2022Alan TaylorInsiderIssued1,083,226A$0.80A$870,913.70
6/22/2022Charles O'Bryan-TearInsiderBuy120,000A$0.45A$53,400.00
See Full Table
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
CLICK HERE TO FIND OUT MORE

SEC Filings (Institutional Ownership Changes) for Clarity Pharmaceuticals (ASX:CU6)

10.73% of Clarity Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
Read More on Clarity Pharmaceuticals

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Who are the company insiders with the largest holdings of Clarity Pharmaceuticals?

Clarity Pharmaceuticals' top insider shareholders include:
  1. Alan Taylor (Insider)
  2. Charles O'Bryan-Tear (Insider)
  3. Colin Biggin (Insider)
Learn More about top insider investors at Clarity Pharmaceuticals.
No Matter The Market, Options Trading Could Earn You More
There’s no way to predict Wall Street’s future, but by using options trading, you have the opportunity to take advantage of any trend. Expert Wendy Kirkland explains how in her latest free guide.
Download it for free here!